

Safety and Effectiveness of MVA-BN vaccination against mpox infection in at-risk individuals in Germany (SEMVA^c)

Monkeypox Virus (mpox)

Monkeypox is a disease caused by the monkeypox virus. It has been known since the 1970s and has mostly occurred in West and Central Africa. The current mpox outbreak and its rapid spread, particularly in Europe and North America, differs from previous ones not only geographically but also in terms of transmission and clinical symptoms.

The infection is transmitted by direct skin or mucosal contact, possibly also via droplets. According to current knowledge, most of those affected do not become seriously ill, but painful skin lesions and scarring may occur.

Objective of the SEMVA^c Study

The German Standing Committee on Vaccination (STIKO) recommends immunization with the MVA-BN smallpox vaccine (Imvanex/Jynneos from Bavarian Nordic) as a vaccination for individuals with increased risk of exposure and/or infection, and as prophylaxis after actual mpox exposure. This study investigates the safety and effectiveness of MVA-BN as part of the national vaccination campaign to make a valuable contribution to the management of mpox. For this purpose, in addition to an inclusion visit, participants will regularly receive email questionnaires over a period of one year to investigate the risk of infection and tolerability of vaccination (if you have received mpox vaccination).

Who can participate?

People who received a vaccination or will receive a vaccination as well as people who do not (initially) receive a vaccination can participate in this study. Whether you receive a vaccination **does not** depend on your participation in the study. Vaccination will be given as part of your routine medical care. If you participate and do not initially receive a vaccination, but in the future receive and accept a regular offer of vaccination, participation is of course still possible.

- Age ≥18
- Men and trans* persons who have sex with men (MSM) and/or trans* persons
- No known mpox disease before 1st vaccination

You will receive money for your participation in the SEMVA^c study.

Are you interested ?

For more information, please feel free to contact your attending doctor.

Study lead: Prof. Dr. med. Leif Erik Sander, Priv. Doz. Dr. med. Florian Kurth
Charité – Universitätsmedizin Berlin. Department of Infectious Diseases and Respiratory Medicine
Augustenburger Platz 1, 13353 Berlin
www.semvac.de

